Lv4
430 积分 2023-10-13 加入
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
12天前
已完结
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
21天前
已完结
Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts
21天前
已完结
Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives
1个月前
已完结
The recent advance and prospect of poly(ADP‐ribose) polymerase inhibitors for the treatment of cancer
1个月前
已完结
PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments
1个月前
已完结
The complex universe of inactive PARP1
1个月前
已完结
A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors’ failure: a review of current and investigational treatment for HR+/Her2- breast cancer
1个月前
已完结
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations
2个月前
已完结
Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies
2个月前
已完结
皖公网安备34019202002308
